Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Paediatric Patients With Alagille Syndrome
NCT01903460 is registered in ClinicalTrials.gov with Mirum Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Paediatric Patients With Alagille Syndrome
- Lead sponsor
- Mirum Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2013
- Completion date
- March 31, 2015
- Enrollment
- 20 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.